Mind Medicine (MindMed)

Mind Medicine's stock rose about 9.6% after reports of a bill in New Jersey backed by a health committee. The draft envisages regulated therapeutic access to psilocybin, with licensing for production, testing, transport, distribution and sale, five license categories and a Psilocybin Advisory Board. A social program is intended to ease access for low-income patients; the target for enactment is the 2026 legislative session. » More on de.investing.com

MindMed said at the Stifel 2025 Healthcare Conference that it has made significant progress in two phase‑3 programs for MM‑120 to treat generalized anxiety disorder and major depression. The company secured net proceeds of USD 242 million, extending its cash runway to the end of 2028. First regulatory‑relevant study results are expected in 2025, with initial depression readouts in mid‑2026; MindMed aims for a rapid regulatory filing 9–12 months after data become available. The company emphasized a constructive dialogue with the FDA and is targeting MM‑120 as a best‑in‑class therapy in the psychiatry market. » More on de.investing.com

Mind Medicine reported Q3 2025 EPS of -$0.78, a 56% miss versus the consensus of -$0.50. Net loss widened to $67.3 million on higher R&D and administrative expenses, while cash balances stood at $209.1 million. A capital raise generated $258.9 million and secures liquidity through 2028; the stock was little changed after hours (+0.26%). The company highlights pipeline progress, including MM120 in Phase 3 for GAD and MDD and plans for MM402 in Phase 2A, with key study readouts expected in 2026. » More on de.investing.com